Qiu-Sheng YIN, Bing SHI, Lan Dong, Lei BI. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure[J]. Journal of Geriatric Cardiology, 2014, 11(1): 79-82. DOI: 10.3969/j.issn.1671-5411.2014.01.014
Citation: Qiu-Sheng YIN, Bing SHI, Lan Dong, Lei BI. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure[J]. Journal of Geriatric Cardiology, 2014, 11(1): 79-82. DOI: 10.3969/j.issn.1671-5411.2014.01.014

Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure

  • Background Heart failure (HF) is a common disease with complex pathophysiological causes. The diagnosis of HF commonly relies on comprehensive analyses of medical history and symptoms, and results from echocardiography and biochemical tests. Galectin-3, a relatively new biomarker in HF, was approved by the US Food and Drug Administration in 2010 as a marker in the stratification of risk for HF. We assessed galectin-3 as a biomarker for HF diagnosis in patients with preserved ejection fraction (pEF) and compared its performance with that of B-type natriuretic peptide (BNP). Methods Thirty-five pEF patients with HF (HFpEF group) and 43 pEF patients without HF (control group) were enrolled. Plasma levels of galectin-3 and BNP in HFpEF and control subjects were determined. Sensitivity, specificity, predictive values, and accuracy of galectin-3 and BNP as markers for HF diagnosis were calculated and compared. Results Levels of galectin-3 and BNP were 23.09 ± 6.97 ng/mL and 270.46 ± 330.41 pg/mL in the HFpEF group, and 16.74 ± 2.75 ng/mL and 59.94 ± 29.93 pg/mL in the control group, respectively. Differences in levels of galectin-3 and BNP between the two groups were significant (P P P P > 0.05). Areas under the receiver operating characteristic curve (95% confidence interval) were 0.891 (0.808–0.974) and 0.896 (0.809–0.984) for galectin-3 and BNP, respectively, with no significant difference between the two values (P > 0.05). Conclusions The level of galectin-3 is significantly elevated in patients with HF. Galectin-3 and BNP are useful biomarkers for the diagnosis of HF in patients with pEF.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return